Baird reiterates Immunocore stock rating on combination therapy data

Baird maintained an Outperform rating and $84.00 price target for Immunocore (IMCR), citing positive Phase 1/2 data for a combination therapy in uveal melanoma. The stock trades at $29.13, with analysts noting potential undervaluation. IMCR reported $429M revenue over the last year, with 13% growth but no profitability. Five analysts revised earnings upwards.

Original reporting
Published Nov 16, 2026, 6:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 6:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$IMCR
Bullish
medium confidence
Mentioned
$IMCR
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IMCRBullishLow
01

Why it matters

The main tradable element is the reiterated rating plus a specific $84 price target, justified by durability improvements versus monotherapy in first-line uveal melanoma and supportive cutaneous melanoma monotherapy/combination rationale.

02

Market read

For IMCR, the note can support near-term sentiment and positioning, but it is not a new clinical filing or regulatory decision.

03

What to watch

The article notes IMCR remains unprofitable; traders may discount upside until profitability path, larger trial readouts, or regulatory milestones de-risk the program.

Relevance 4/10Novelty 4/10Timing: analyst note coverage, no scheduled macro catalyst

Background

Baird’s note reiterates a bullish stance on Immunocore’s melanoma combination approach, referencing SITC-presented Phase 1/2 results.

Company-level read

Ticker impact

$IMCRBullishMedium confidence
Context

Baird reiterated an Outperform rating and $84 price target for Immunocore, citing SITC Phase 1/2 data where Kimmtrak plus brenetafusp showed greater durability than monotherapy in first-line uveal melanoma.

Expected impact

Likely upward bias as traders price in continued confidence in the combination regimen and the reiterated higher target.

Evidence & confidence

The article is an analyst reiteration, but it anchors the thesis to specific clinical durability data and a fresh price-target number, which can move sentiment even without new company filings.

Market effects

Reinforces positive sentiment toward oncology immunotherapy combination strategies and melanoma franchise durability narratives.

No clear regional spillover beyond US biotech sentiment.

Limited, as the catalyst is company-specific clinical data and a US analyst note.

Counterpoint

Combination-therapy durability from early Phase 1/2 data may not translate into definitive efficacy, safety, and regulatory outcomes, so the target could be overly optimistic.

Key entities

  • Immunocore Holdings

    NASDAQ-listed biotech focused on immunotherapy, subject of the analyst reiteration tied to SITC clinical data.

  • Baird

    Brokerage reiterating Outperform and $84 price target for IMCR.

  • Kimmtrak

    Immunocore therapy referenced as monotherapy and in combination with brenetafusp.

  • brenetafusp

    Combination partner referenced in Phase 1/2 durability comparisons.

  • SITC

    Conference where the Phase 1/2 combination therapy data were presented.

Related articles

$IMCRMed

Immunocore 3Q 2026: Revenue $102.22M, EPS ($0.28) — 10-Q Summary

Immunocore reported a 1.4% YoY revenue decline to $102.22M in Q3 2026, with a widened net loss of $14.22M. U.S. sales fell due to stocking adjustments and fewer sales weeks, partially offset by European and international growth. R&D spending increased, impacting results. KIMMTRAK is approved in 39 countries, and TEBE-AM Phase 3 trial enrollment is complete, with data expected in Q2 2027.